Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: May 27, 2024

Notch signaling, renowned for its role in regulating cell fate, organ development, and tissue homeostasis across metazoans, is highly conserved throughout evolution. The receptor ligands are transmembrane proteins containing epidermal growth factor-like repeat sequences, typically necessitating receptor-ligand interaction to initiate classical signaling transduction. Accumulating evidence indicates that the pathway serves as both an oncogenic factor a tumor suppressor various cancer types. Dysregulation of this promotes epithelial-mesenchymal transition angiogenesis malignancies, closely linked proliferation, invasion, metastasis. Furthermore, contributes maintaining stem-like properties cells, thereby enhancing invasiveness. regulatory metabolic reprogramming microenvironment suggests pivotal involvement balancing suppressive effects. Moreover, implicated conferring chemoresistance cells. Therefore, comprehensive understanding these biological processes crucial developing innovative therapeutic strategies targeting signaling. This review focuses on research progress cancers, providing in-depth insights into potential mechanisms regulation occurrence progression cancer. Additionally, summarizes pharmaceutical clinical trials therapy, aiming offer new human malignancies.

Language: Английский

---

Emerging therapies in cancer metabolism

Cell Metabolism, Journal Year: 2023, Volume and Issue: 35(8), P. 1283 - 1303

Published: Aug. 1, 2023

Language: Английский

---

Regulation of nucleotide metabolism in cancers and immune disorders

Trends in Cell Biology, Journal Year: 2023, Volume and Issue: 33(11), P. 950 - 966

Published: March 24, 2023

Language: Английский

---

Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma

Cancer Cell, Journal Year: 2022, Volume and Issue: 40(12), P. 1488 - 1502.e7

Published: Nov. 10, 2022

Language: Английский

---

Emerging roles of nucleotide metabolism in cancer

Trends in cancer, Journal Year: 2023, Volume and Issue: 9(8), P. 624 - 635

Published: May 10, 2023

Language: Английский

---

Mass spectrometry imaging methods for visualizing tumor heterogeneity

Current Opinion in Biotechnology, Journal Year: 2024, Volume and Issue: 86, P. 103068 - 103068

Published: Feb. 7, 2024

Profiling spatial distributions of lipids, metabolites, and proteins in tumors can reveal unique cellular microenvironments provide molecular evidence for cancer cell dysfunction proliferation. Mass spectrometry imaging (MSI) is a label-free technique that be used to map biomolecules situ. Here, we discuss current progress applying MSI uncover heterogeneity tumors. First, the analytical strategies profile small molecules are outlined, methods multimodal maximize biological information highlighted. Second, present summarize insights obtained by tumor tissue. Finally, important considerations designing experiments several challenges.

Language: Английский

---

Metabolism-driven chromatin dynamics: Molecular principles and technological advances

Molecular Cell, Journal Year: 2025, Volume and Issue: 85(2), P. 262 - 275

Published: Jan. 1, 2025

Language: Английский

---

Regulators of mitonuclear balance link mitochondrial metabolism to mtDNA expression

Nature Cell Biology, Journal Year: 2023, Volume and Issue: 25(11), P. 1575 - 1589

Published: Sept. 28, 2023

Language: Английский

---

Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 835 - 865

Published: May 20, 2024

Diffuse midline glioma (DMG), including tumors diagnosed in the brainstem (diffuse intrinsic pontine - DIPG), is primary cause of brain tumor-related death pediatric patients. DIPG characterized by a median survival <12 months from diagnosis, harboring worst 5-year rate any cancer. Corticosteroids and radiation are mainstay therapy; however, they only provide transient relief devastating neurological symptoms. Numerous therapies have been investigated for DIPG, but majority unsuccessful demonstrating benefit beyond alone. Although many barriers hinder drug delivery one most significant challenges blood-brain barrier (BBB). Therapeutic compounds must possess specific properties to enable efficient passage across BBB. In cancer, BBB referred as tumor (BBTB), where disrupt structure function BBB, which may opportunities delivery. However, biological characteristics brainstem's BBB/BBTB, both under normal physiological conditions response poorly understood, further complicates treatment. Better characterization changes that occur BBB/BBTB patients essential, this informs future treatment strategies. Many novel technologies bypass or convection enhanced delivery, focused ultrasound, nanoparticle-mediated intranasal all yet be clinically established DIPG. Herein, we review what known about discuss current status, limitations, advances conventional treatments improving

Language: Английский

---

DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer

Oncogene, Journal Year: 2024, Volume and Issue: 43(19), P. 1399 - 1410

Published: March 13, 2024

Language: Английский

---